Clinical TrialsOpus Reports BEST1 Retinal Sensitivity Gains and Sustained LCA5 Vision Impr... Opus Reports BEST1 Retinal Sensitivity Gains and Sustained LCA5 Vision Impr... Read Post »
Regulatory & Health PolicyFDA Launches Cross-Center Framework to Standardize Rare Disease Drug Review FDA Launches Cross-Center Framework to Standardize Rare Disease Drug Review Read Post »
Clinical TrialsOsivax OVX836 Misses Phase 2b Influenza Vaccine Target Osivax OVX836 Misses Phase 2b Influenza Vaccine Target Read Post »
Clinical TrialsGalderma Reports Positive Itch Response for Nemolizumab in Young Children Galderma Reports Positive Itch Response for Nemolizumab in Young Children Read Post »
Clinical TrialsEC-104 Shows Durable Improvement in Phase 2 DME Trial EC-104 Shows Durable Improvement in Phase 2 DME Trial Read Post »
Clinical TrialsLilly’s Omvoh Achieves Deeper Remission in IBD Lilly’s Omvoh Achieves Deeper Remission in IBD Read Post »
Health Tidings Mergers & AcquisitionsAdlai Nortye Partners with Eli Lilly and Merck KGaA for Phase I ADC Combina... Adlai Nortye Partners with Eli Lilly and Merck KGaA for Phase I ADC Combina... Read Post »
Clinical TrialsinvIOs’ APN401 Shows Early Safety Findings and Disease Stabilization in A... invIOs’ APN401 Shows Early Safety Findings and Disease Stabilization in A... Read Post »
Health TidingsAquestive’s Anaphylm NDA Resubmission Accepted by FDA Aquestive’s Anaphylm NDA Resubmission Accepted by FDA Read Post »
Clinical TrialsCellectar’s Iopofosine I 131 Shows 87.5% Response Rate in WM Cellectar’s Iopofosine I 131 Shows 87.5% Response Rate in WM Read Post »
Health TidingsAstraZeneca, insitro Strike $1.5 Billion AI Drug Discovery Deal for MASH an... AstraZeneca, insitro Strike $1.5 Billion AI Drug Discovery Deal for MASH an... Read Post »
Health TidingsVividion Advances WRN Inhibitor VVD-214 Into Phase 2 Trial with Pembrolizum... Vividion Advances WRN Inhibitor VVD-214 Into Phase 2 Trial with Pembrolizum... Read Post »
Health TidingsSarepta’s SRP-1003 Achieves Up to 80% Nuclear DMPK RNA Knockdown in Precl... Sarepta’s SRP-1003 Achieves Up to 80% Nuclear DMPK RNA Knockdown in Precl... Read Post »
Health TidingsPonatinib Plus Blinatumomab Improves 24-Month Event-Free Survival in Ph-Pos... Ponatinib Plus Blinatumomab Improves 24-Month Event-Free Survival in Ph-Pos... Read Post »
Health TidingsElevar Resubmits Rivoceranib-Camrelizumab NDA After Three FDA CRLs, Despite... Elevar Resubmits Rivoceranib-Camrelizumab NDA After Three FDA CRLs, Despite... Read Post »
New Drug ApprovalFDA Expands ANKTIVA Approval to High-Grade Papillary-Only Bladder Cancer FDA Expands ANKTIVA Approval to High-Grade Papillary-Only Bladder Cancer Read Post »
Clinical TrialsZenas Obexelimab Show Sustained Flare Control, Reduced Steroid Toxicity in ... Zenas Obexelimab Show Sustained Flare Control, Reduced Steroid Toxicity in ... Read Post »
Clinical TrialsVanda VQW-765 Phase 3 Trial Fails in Social Anxiety Vanda VQW-765 Phase 3 Trial Fails in Social Anxiety Read Post »
Clinical TrialsArrowhead ARO-MAPT Cuts CSF Tau by 73% in Phase 1/2a Arrowhead ARO-MAPT Cuts CSF Tau by 73% in Phase 1/2a Read Post »
Health TidingsFDA Accepts Tabelecleucel Resubmission for EBV-Positive PTLD FDA Accepts Tabelecleucel Resubmission for EBV-Positive PTLD Read Post »
Clinical TrialsSitryx Reports Early Improvements in Atopic Dermatitis With SYX-5219 Sitryx Reports Early Improvements in Atopic Dermatitis With SYX-5219 Read Post »
Clinical TrialsTAK-881 Meets Primary PK Endpoint, Reducing Infusion Burden in PID TAK-881 Meets Primary PK Endpoint, Reducing Infusion Burden in PID Read Post »
Health TidingsVir and Gilead Partner on T-Cell Engagers for Solid Tumors Vir and Gilead Partner on T-Cell Engagers for Solid Tumors Read Post »
Health TidingsUnited Therapeutics Presents PAH, IPF and PH-ILD Data at CHEST 2026 United Therapeutics Presents PAH, IPF and PH-ILD Data at CHEST 2026 Read Post »
Health TidingsBMS Reports Phase 3 PFS Benefit with RYZ101 in Advanced GEP-NETs BMS Reports Phase 3 PFS Benefit with RYZ101 in Advanced GEP-NETs Read Post »
Health TidingsAlentis and PinotBio Expand Claudin-1 ADC Development Alentis and PinotBio Expand Claudin-1 ADC Development Read Post »
Clinical TrialsEntrada Reports Early Dystrophin Increase with ENTR-601-45 in DMD Entrada Reports Early Dystrophin Increase with ENTR-601-45 in DMD Read Post »
Clinical TrialsVerastem’s VS-7375 Shows 50% Response Rate in Pancreatic Cancer Verastem’s VS-7375 Shows 50% Response Rate in Pancreatic Cancer Read Post »
Health Tidings Mergers & AcquisitionsEton Secures U.S. Rights to LIBERVANT Seizure Rescue Film Eton Secures U.S. Rights to LIBERVANT Seizure Rescue Film Read Post »
Health TidingsWhat Is SD-101? Paradigm’s Investigational Therapy for Epidermolysis Bull... What Is SD-101? Paradigm’s Investigational Therapy for Epidermolysis Bull... Read Post »
Health Tidings Mergers & AcquisitionsGenerate Signs $1.2B Milestone Deal with Zealand for AI-Designed Protein Dr... Generate Signs $1.2B Milestone Deal with Zealand for AI-Designed Protein Dr... Read Post »
Health TidingsOnswik Secures UK Authorisation as Once-Weekly Insulin Offers an Alternativ... Onswik Secures UK Authorisation as Once-Weekly Insulin Offers an Alternativ... Read Post »
Clinical TrialsSKYRIZI Achieves 35.8% Remission in AFFIRM Crohn’s Trial SKYRIZI Achieves 35.8% Remission in AFFIRM Crohn’s Trial Read Post »
Clinical TrialsBiomea’s Oral GLP-1 Candidate BMF-650 Shows Early Weight Loss Biomea’s Oral GLP-1 Candidate BMF-650 Shows Early Weight Loss Read Post »
Clinical TrialsBeam Reports Improved Fasting Tolerance With BEAM-301 Base Editing in GSDIa Beam Reports Improved Fasting Tolerance With BEAM-301 Base Editing in GSDIa Read Post »
Health TidingsEntera Bio Reports Up to 4.23% Hip BMD Gain with Oral EB613 in Osteoporosis... Entera Bio Reports Up to 4.23% Hip BMD Gain with Oral EB613 in Osteoporosis... Read Post »
Health TidingsNImmune Reports Omilancor Cuts Biologic-Refractoriness Gene Signature by Ov... NImmune Reports Omilancor Cuts Biologic-Refractoriness Gene Signature by Ov... Read Post »
Health Tidings Mergers & AcquisitionsPrelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Brea... Prelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Brea... Read Post »
Health TidingsZydus, Formycon Advance First Publicly Announced Keytruda Biosimilar into F... Zydus, Formycon Advance First Publicly Announced Keytruda Biosimilar into F... Read Post »
Clinical Trialsāshibio Reports 86.2% Lower FOP Flare-Up, Advances Vantictumab for ADO2 āshibio Reports 86.2% Lower FOP Flare-Up, Advances Vantictumab for ADO2 Read Post »
Clinical TrialsTREMFYA Shows Fistula Remission in Crohn’s Disease TREMFYA Shows Fistula Remission in Crohn’s Disease Read Post »
Clinical TrialsSyndax Ends Axatilimab Development in IPF After Phase 2 Failure Syndax Ends Axatilimab Development in IPF After Phase 2 Failure Read Post »
Health TidingsEleven Therapeutics Spinout Undecimal Bio Raises $18M to Advance siRNA Deli... Eleven Therapeutics Spinout Undecimal Bio Raises $18M to Advance siRNA Deli... Read Post »
Clinical TrialsBioNTech BNT113 Misses PFS Endpoint in HPV16+ HNSCC Trial BioNTech BNT113 Misses PFS Endpoint in HPV16+ HNSCC Trial Read Post »
Health Tidings Mergers & AcquisitionsRoche and Rona Sign $1.16B Deal for ALK7-Targeting RNAi Obesity Candidate Roche and Rona Sign $1.16B Deal for ALK7-Targeting RNAi Obesity Candidate Read Post »
Health TidingsRegeneron Reports Zero New Bone Lesions With Pasatru in OPTIMA Extension Regeneron Reports Zero New Bone Lesions With Pasatru in OPTIMA Extension Read Post »
Health TidingsTREMFYA Delivers 3-Year Clinical and Endoscopic Remission in Crohn’s Dise... TREMFYA Delivers 3-Year Clinical and Endoscopic Remission in Crohn’s Dise... Read Post »
Health TidingsZydus’ Saroglitazar Shows Higher PBC Biochemical Response Across Geog... Zydus’ Saroglitazar Shows Higher PBC Biochemical Response Across Geog... Read Post »
Health TidingsImmuron’s Travelan Shows 40% Reduction in ETEC-Associated Travellers’ D... Immuron’s Travelan Shows 40% Reduction in ETEC-Associated Travellers’ D... Read Post »
Clinical TrialsTortugas Reports Positive Phase 2b Results for Obuprazine in Schizophrenia Tortugas Reports Positive Phase 2b Results for Obuprazine in Schizophrenia Read Post »
